Vasamed (OTCMKTS:VSMD – Get Free Report) and Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk and dividends.
Profitability
This table compares Vasamed and Tandem Diabetes Care’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vasamed | N/A | N/A | N/A |
| Tandem Diabetes Care | -9.20% | -53.88% | -7.88% |
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Vasamed and Tandem Diabetes Care, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vasamed | 0 | 0 | 0 | 0 | 0.00 |
| Tandem Diabetes Care | 1 | 10 | 8 | 2 | 2.52 |
Valuation & Earnings
This table compares Vasamed and Tandem Diabetes Care”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vasamed | N/A | N/A | N/A | N/A | N/A |
| Tandem Diabetes Care | $1.03 billion | 0.99 | -$204.71 million | ($1.40) | -10.59 |
Vasamed has higher earnings, but lower revenue than Tandem Diabetes Care.
Summary
Tandem Diabetes Care beats Vasamed on 5 of the 8 factors compared between the two stocks.
About Vasamed
Vasamed Incorporated designs, licenses, manufactures, and distributes products, software, and services for assessing and managing hemodynamic health in the United States. It offers SensiLase PAD-IQ, which supports skin perfusion pressure, pulse volume recording, and ankle brachial index calculation for Doppler-obtained pressures; and Wound Imaging & SmartDraw wound measurement systems. The company also provides PAD-IQ Studycast that provides rapid transmission of diagnostic tests to vascular specialist for interpretation of results and medically indicated therapeutic intervention; and custom carrying case to secure and protect the PAD-IQ system. It serves clinicians and patients. The company was founded in 1988 and is headquartered in Eden Prairie, Minnesota.
About Tandem Diabetes Care
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Receive News & Ratings for Vasamed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vasamed and related companies with MarketBeat.com's FREE daily email newsletter.
